I-Crizotinib CAS 877399-52-5 Assay ≥99.0% API Factory High Quality
I-Shanghai Ruifu Chemical Co., Ltd. ingumkhiqizi ohamba phambili we-Crizotinib (CAS: 877399-52-5) enekhwalithi ephezulu.I-Ruifu Chemical inganikeza ukulethwa komhlaba wonke, intengo encintisanayo, isevisi enhle kakhulu, amanani amancane kanye nenqwaba etholakalayo.Thenga i-Crizotinib,Please contact: alvin@ruifuchem.com
| Igama Lekhemikhali | I-Crizotinib |
| Omqondofana | Xalkori;PF-02341066;I-Crozotinib;Crizotinib Xalkori;3--[1-(2,6-Dichloro-3-Fluoro-phenyl)-ethoxy]-5-(1-Piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine;(R)-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine |
| Inombolo ye-CAS | 877399-52-5 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
| I-Molecular Formula | I-C21H22Cl2FN5O |
| Isisindo samangqamuzana | 450.34 |
| I-Melting Point | 192℃ |
| Ukuminyana | 1.47±0.10 g/cm3 |
| Izinga Lokushisa Lesitoreji | Ukushisa Kwegumbi |
| Umsuka | Shanghai, China |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | Impushana Emhlophe Kuya Kumhlophe |
| Ukuhlonza | Nge-IR, HPLC |
| Ukucaca Kwesixazululo | Vumelana Nezinga |
| Ukulahlekelwa Ekumisweni | ≤1.00% |
| Izinsalela ekushiseni | ≤0.50% |
| Ukungcola Okuhlobene | (nge-HPLC) |
| Ukungcola Okukodwa | ≤0.50% |
| Ukungcola Okuphelele | ≤1.00% |
| Izinsimbi Ezisindayo | ≤20ppm |
| Isivivinyo | ≥99.0% |
| Izincibilikisi Ezisele | Hlangana nencazelo |
| I-Shelf Life | Izinyanga ezingama-24 |
| Izinga Lokuhlola | I-Enterprise Standard |
Iphakheji:Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina isiqukathi sivalwe ngokuqinile futhi usigcine endaweni epholile, eyomile (2~8℃) nengena umoya omuhle kude nezinto ezingahambelani.Vikela ekukhanyeni nakumswakama.
Ukuthumela:Zilethe emhlabeni wonke ngendiza, yi-FedEx/DHL Express.Nikeza ukulethwa okusheshayo nokuthembekile.
Incazelo Yezokuphepha 24/25 - Gwema ukuthintana nesikhumba namehlo.
Omazisi be-UN UN 3077 9 / PGIII
I-WGK Germany 3
I-HS Code 2933990099
I-Hazard Class IRRITANT
I-Crizotinib (i-CAS 877399-52-5), (i-Crizotinib, i-Xalkori R), i-ATP enamandla futhi ekhethiwe yokuncintisana ye-molecule encane inhibitor ye-ALK ne-c-Met.Ngo-Agasti 2011, i-United States FDA igunyaze i-Crizotinib yokwelashwa kwe-anaplastic lymphoma kinase (ALK) yahlela kabusha umdlavuza wamaphaphu ongewona wamaseli amancane (NSCLC).I-Crizotinib iyi-dual ATP inhibitor yokuncintisana ye-tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50=8 nM) kanye ne-ALK (cellular IC50=20 nM), kokubili okuyizinjongo ezibalulekile zokwelashwa ngamakhemikhali omdlavuza.Lapho i-crizotinib ihlolelwa ukukhetha uma iqhathaniswa namanye ama-kinase kwatholakala ukuthi ine-enzyme IC50 phakathi kokuphindaphinda okungu-100 kwe-c-MET kwe-13 ye-120 kinases ehloliwe.Ezivivinyweni zamaselula, i-crizotinib itholwe ivimbela i-RON (i-recepteur d'origine nantais) kinase ngewindi lokukhetha eliphindwe izikhathi ezingu-10 ngaphezu kwe-c-MET.
I-Crizotinib (PF-02341066) I-Crizotinib iyi-c-Met enamandla ne-ALK inhibitor, amanani e-IC50 ku-cell assay ayengu-11 nM kanye no-24 nM, ngokulandelanayo.Futhi iyi-inhibitor enamandla ye-ROS1 enenani le-Ki elingaphansi kuka-0.025 nM.I-Crizotinib ingenza i-autophagy emigqeni yamaseli omdlavuza wamaphaphu ehlukahlukene ngokuvimbela indlela ye-STAT3.
I-Crizotinib iyi-dual inhibitor enamandla futhi ekhethiwe ye-mesenchymal-epithelial transition factor (c-MET) kinase kanye ne-anaplastic lymphoma kinase (ALK).I-Crizotinib iyi-ejenti engase ibe ne-antitumor.Ngo-Agasti 2011, i-United States FDA igunyaze i-crizotinib yokwelashwa kwe-anaplastic lymphoma kinase (ALK) yahlela kabusha umdlavuza wamaphaphu ongewona wamaseli amancane (NSCLC).
I-Crizotinib (Xalkori(R), i-Pfizer), egunyazwe ngo-2011, kwakuyi-inhibitor yokuqala evunyelwe eqondise i-anaplastic lymphoma kinase (ALK).I-ROS protooncogene 1-encoded kinase (ROS1) yekilasi le-tyrosine kinase insulin receptor kanye ne-MET proto-oncogene-encoded kinase yekilasi le-hepatocyte growth factor receptor (HGFR) amanye ama-kinase aqondiswe yi-crizotinib.Lapho kuvunywa ngo-2011, i-crizotinib yaba eyokuqala umuthi oqondiswe ngqo ezigulini ze-NSCLC.Kodwa-ke, ukumelana ne-crizotinib kuvame ukubonwa cishe ezinyangeni ze-8 ngemuva kokusetshenziswa kokuqala futhi ngaphezu kwesigamu seziguli eziphathwe nge-crizotinib zithole imiphumela emibi yesisu.Ngo-2016, i-crizotinib yagunyazwa futhi i-ROS1-positive NSCLC yi-FDA.
I-Crizotinib (i-Xalkori) iyi-oral receptor tyrosine kinase inhibitor eboniswe ekwelapheni iziguli ezinomdlavuza wamaphaphu ongewona omncane noma we-metastatic (NSCLC).Imiphumela emibi evamile ngokusetshenziswa kwe-Xalkori ihlanganisa ukutheleleka okuphezulu kokuphefumula, isicanucanu, ukuhlanza, ubuhlungu besisu, ukuncipha kwesifiso sokudla, ukuqwasha, isiyezi, umuzwa wokukhathala, isifo sohudo, ukuqunjelwa, ukuqubuka noma ukulunywa, izimpawu ezibandayo (ikhala eligcwele ikhala, ukuthimula, umphimbo obuhlungu), ukuba ndikindiki noma ukuluma, noma ukuvuvukala ezandleni noma ezinyaweni zakho.
